| Oct 17 |
Amicus Therapeutics Settles Patent Lawsuit Teva Pharmaceuticals Over Generic Version Of Its Rare Genetic Disorder Drug
|
| Oct 15 |
Immuneering rises on orphan drug designation for treatment of pancreatic cancer
|
| Oct 11 |
Teva Pays $450M To Resolve Alleged Kickback, Price-Fixing Schemes
|
| Oct 11 |
Update: Teva Pharmaceutical to Pay $450 Million to Settle Anti-Kickback Allegations
|
| Oct 10 |
Teva agrees to pay $425M to settle Copaxone kickback case: DOJ
|
| Oct 10 |
Teva Pharmaceuticals to Pay $450 Million to Settle Kickback Allegations
|
| Oct 10 |
Teva to pay $450 million to resolve US kickback, price-fixing cases
|
| Oct 9 |
Teva Pharmaceutical Industries Ltd (TEVA) Q2 2024 Earnings Call Highlights: Strong Revenue ...
|
| Oct 8 |
TEVA applications for Prolia biosimilar accepted by FDA, EMA
|
| Oct 8 |
Teva Prolia® (Denosumab) Biosimilar Candidate is Accepted for Review by U.S. FDA and EU EMA
|
